Compare Comcast Corporation (CMCSA) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Cassava Sciences Inc — how do they compare? Comcast Corporation trades at $25.64 (market cap $91.02B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Comcast Corporation is far larger — about 1906.2× Cassava Sciences Inc's market cap, and Comcast Corporation pays a 5.15% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| CMCSA | FLNA | |
|---|---|---|
Market Cap | $91.02B | $47.75M |
Sector | Media | Health |
52-Week High | $32.50 | $4.64 |
52-Week Low | $21.92 | $0.87 |
Enterprise Value | $173.74B | -$34.93M |
Dividend Yield | 5.15% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
